Hong Kong firm petitions FDA on acetaminophen equivalency
This article was originally published in The Tan Sheet
Executive SummaryWishing to bring its "effective, safe but cheap drug to U.S. patients," Bright Future Pharmaceutical Lab Ltd. asks FDA to allow the use of GlaxoSmithKline's 500-mg acetaminophen drug Panadol as the reference listed drug in an abbreviated new drug application for the Hong Kong firm's BF-PARADAC. Although the Orange Book contains no RLD identical to BF-PARADAC in dosage form, strength or formulation, Panadol is pharmaceutically and/or therapeutically equivalent to Bright Future's drug, the company says in its ANDA suitability 1petition dated Dec. 17. Bright Future says the bioequivalence study of BF-PARADAC using Panadol as the reference is complete, and asks FDA to suggest another RLD equivalent to its drug
You may also be interested in...
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.